SCHEMBL26075465

SCHEMBL26075465

CSc1ncc2c(n1)N1CCN=C1C(Oc1ccc(N)cc1F)=C2

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.33
▸ MET P08581 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537702 1.00 PTGS2 (0.33) PTGS2MET
SCHEMBL29537104 0.91 MET (0.35) PTGS2MET
SCHEMBL25420591 0.91 MET (0.35) PTGS2MET
SCHEMBL26075415 0.85 MAPK14 (0.37) PTGS2
SCHEMBL29536806 0.84 PDE4B (0.40) MET
SCHEMBL25420084 0.84 PDE4B (0.40) MET
SCHEMBL29537371 0.80 MET (0.32) MET
SCHEMBL29537219 0.78 MAPK14 (0.32) —
SCHEMBL26075423 0.77 RAF1 (0.48) —
SCHEMBL30595902 0.76 MAPK8 (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 PTGS2 2300/4885MET 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback